COMMUNIQUÉS West-GlobeNewswire

INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2018

07/12/2017 - 07:01

Innate Pharma announceS ITS FINANCIAL CALENDAR FOR 2018 Marseille, France, December 7, 2017, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces its financial calendar for [...]

INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018

07/12/2017 - 07:01

INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018 Marseille, le 7 décembre 2017, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui son calendrier financier pour l'année 2018 : 8 [...]

INNATE PHARMA : NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT DECEMBER 4, 2017

07/12/2017 - 07:01

NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT December 4, 2017 Marseille, France, December 7, 2017, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 [...]

INNATE PHARMA : NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 4 DECEMBRE 2017

07/12/2017 - 07:01

nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 4 décembre 2017 Marseille, le 7 décembre 2017, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]

GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $276 Million

07/12/2017 - 03:40

LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]

Resverlogix Repays $68.8 Million Loan

07/12/2017 - 01:16

CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX ) announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of [...]

Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium

07/12/2017 - 00:00

SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to [...]

Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B

06/12/2017 - 23:00

PHILADELPHIA and NEW YORK, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. ( [...]

G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06/12/2017 - 22:54

RESEARCH TRIANGLE PARK, N.C., Dec. 06, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced the grant of an equity inducement award to Barclay (Buck) [...]

Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

06/12/2017 - 22:30

BURLINGTON, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President [...]

US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses

06/12/2017 - 22:29

SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses [...]

Purepoint Uranium Closes Final Tranche of $1,200,000 Private Placement

06/12/2017 - 22:24

Not for Dissemination in the United States or through U.S. Newswire Services TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (TSXV:PTU) (the “ Company ”) is pleased to announce the closing of the [...]

Analogic Announces Results for the First Quarter Ended October 31, 2017 and Declares Quarterly Cash Dividend

06/12/2017 - 22:15

PEABODY, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq: ALOG ), enabling the world's medical imaging and aviation security technology, today announced results for its first quarter ended October [...]

WishBone Medical Inc. Names Jean-Pierre Capdevielle as Chief Strategy Officer and Board Member

06/12/2017 - 21:06

WARSAW, Ind., Dec. 06, 2017 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a new pediatric orthopedic company in Warsaw, Indiana, announced that Jean-Pierre “JP” Capdevielle has taken on the role of Chief Strategy Officer [...]

Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...

06/12/2017 - 19:16

Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and an early response with separation of [...]

Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)

06/12/2017 - 18:10

Objective Response Rate (ORR) = 31% (Centrally Reviewed); 34% (Locally Assessed) Median Duration of Response (DOR) = 9.1 Months (Centrally Reviewed); 7.6 Months (Locally Assessed) Clinical Benefit Rate at 6 Months = 45 [...]

GUERBET : Gadolinium-based contrast agents: update on MHLW decision in Japan

06/12/2017 - 18:05

Villepinte (France), December 6, 2017 (6pm CET) - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, takes note of the decision issued on November 28 by the Japanese [...]

GUERBET : Produits de contraste à base de gadolinium : information sur la décision du Ministère de la Santé au Japon

06/12/2017 - 18:05

Villepinte (France), 6 décembre, 2017 (18:00 CET) - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, prend acte de la décision émise le 28 novembre par le [...]

VALNEVA : Déclaration d'actions et de droits de vote - novembre 2017

06/12/2017 - 18:00

VALNEVA Déclaration d'actions et de droits de vote - NOVEMBRE 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon - Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]